Related references
Note: Only part of the references are listed.Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Santiago Barrio et al.
LEUKEMIA (2019)
The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma
Dong Hoon Lee et al.
MOLECULAR CARCINOGENESIS (2019)
HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma
Hye-Rim Won et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors
Andrej Besse et al.
CELL CHEMICAL BIOLOGY (2019)
A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells
Hye-Rim Won et al.
MOLECULAR CARCINOGENESIS (2018)
Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma
E. Malek et al.
LEUKEMIA (2017)
Panobinostat for the management of multiple myeloma
Dharshan Sivaraj et al.
FUTURE ONCOLOGY (2017)
Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells
Jonathan Iaconelli et al.
ACS CHEMICAL BIOLOGY (2017)
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
CLINICAL CANCER RESEARCH (2017)
HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis
Hyun-Wook Ryu et al.
CANCER LETTERS (2017)
HDAC6 regulates sensitivity to cell death in response to stress and post-stress recovery
Hyun-Wook Ryu et al.
CELL STRESS & CHAPERONES (2017)
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling
Xing-Ding Zhang et al.
CANCER CELL (2016)
Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
G. P. Soriano et al.
LEUKEMIA (2016)
miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy
Yan Sun et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis
Juwon Park et al.
BMB REPORTS (2014)
The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Zachary Miller et al.
CURRENT CANCER DRUG TARGETS (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs
Fengdong Cheng et al.
JOURNAL OF IMMUNOLOGY (2014)
被撤回的出版物: IN Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells (Retracted article. See vol. 18, pg. 1181, 2019)
Girija Dasmahapatra et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
Jesus F. San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors
Eunhyun Choi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Peter Walter et al.
SCIENCE (2011)
Routine Health Maintenance in Patients Living With Multiple Myeloma: Survivorship Care Plan of the International Myeloma Foundation Nurse Leadership Board
Elizabeth Bilotti et al.
CLINICAL JOURNAL OF ONCOLOGY NURSING (2011)
Management of treatment-related adverse events in patients with multiple myeloma
Maria-Victoria Mateos
CANCER TREATMENT REVIEWS (2010)
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
Sundar Jagannath et al.
LEUKEMIA RESEARCH (2010)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
D. Gutman et al.
LEUKEMIA (2009)
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
Madeleine Duvic et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
Antonia Busse et al.
CANCER (2008)
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells
Hongtao Gu et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response
SoHee Kwon et al.
GENES & DEVELOPMENT (2007)
From the bench to the bedside: emerging new treatments in multiple myeloma
Constantine S. Mitsiades et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma
Paul G. Richardson et al.
CURRENT OPINION IN ONCOLOGY (2006)
JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways
M Lauricella et al.
APOPTOSIS (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
NF-κB RelA phosphorylation regulates RelA acetylation
LF Chen et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Drug resistance and drug development in multiple myeloma
WS Dalton
SEMINARS IN ONCOLOGY (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38
LV Madrid et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
